Trontinemab clinical trials
Also written RO7126209.
How each study uses trontinemab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the trontinemab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
5 studies that test it; most in 2025 (2)
| Year | Studies |
|---|---|
| 2019 | 1 |
| 2021 | 1 |
| 2025 | 2 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 0
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test trontinemab.
Studies
Open first, then newest update. How each study uses trontinemab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's DiseaseRecruitingPhase 3Hoffmann-La RocheNCT07717411Written as Trontinemab
- A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's DiseaseActive, not recruitingPhase 3Hoffmann-La RocheNCT07170150Written as Trontinemab
- A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's DiseaseActive, not recruitingPhase 3Hoffmann-La RocheNCT07169578Written as Trontinemab
- Brainshuttle AD: A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7126209 Following Intravenous Infusion in Participants With Prodromal or Mild to Moderate Alzheimer's DiseaseActive, not recruitingPhase 1/2Hoffmann-La RocheNCT04639050Written as RO7126209
- A Single Ascending Dose Study to Investigate the Safety, Tolerability, Immunogenicity and Pharmacokinetics of Intravenously Administered RO7126209 in Healthy ParticipantsCompletedPhase 1Hoffmann-La RocheNCT04023994Written as RO7126209
Codes
What other systems call trontinemab · ClinicalTrials.gg INT017343
- UNII (FDA) N0GBZ1GWC2TRONTINEMABOne source FDA
- NCI Thesaurus C188602TrontinemabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | N0GBZ1GWC2 | TRONTINEMAB | One source FDA |
| NCI Thesaurus | C188602 | Trontinemab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.